
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Bal Harbour, Fla. - Atopic dermatitis treatments are evolving to focus not only on treating flares but also maintaining the disease and offering patients with different severities long-term treatment options that focus on safely keeping the skin condition at bay.